Stella has a US menopause clinic and a separately presented UK service. That geographic distinction comes before any comparison of price or treatment access. A pound-denominated consultation or UK delivery description is not evidence of what a US patient would purchase.
This review is based on the US homepage and US FAQ checked September 28, 2026. We did not register, consult a clinician or use the app. The focus is how clinical visits, wellness support and pharmacy prescriptions fit together, with the unresolved personal coverage and treatment questions left open.
Stella publishes US visit prices and an estrogen-prescribing pathway; coaching access, national reach and average copays do not guarantee individual coverage or treatment.
Use the US service record for US care questions
The US Stella homepage describes a virtual menopause clinic with board-certified clinicians, visits, care coordination and prescriptions sent to a preferred pharmacy. It advertises clinicians in 50 states. That is a published footprint rather than evidence that an appointment with a particular clinician is available at a chosen time.
The US FAQ says the service is designed for women aged 35–70, including those still menstruating or uncertain whether symptoms relate to menopause. The age range is a platform description, not a prescription rule. Confirm location, appointment availability and the clinical assessment required. This review does not import eligibility rules, prices or delivery promises from Stella’s UK pages.
The app follows the clinical visit rather than replacing it
Stella says the app becomes available after the first visit and includes wellness coaching, symptom tracking, habit-building material, audio resources and menopause education. Its service description separately identifies virtual visits with menopause specialists. These components have different roles even when sold as a coordinated experience.
Ask who answers a medical question, how a coach passes a concern to the clinical team and when another appointment is needed. Unlimited coaching does not establish unlimited immediate prescribing access or emergency monitoring. Gennev’s doctor-and-dietitian model offers a useful comparison of professional roles, while Winona’s messaging model illustrates why ongoing access needs to be defined more precisely than a general support claim.
Estrogen is offered alongside other treatment routes
The US FAQ explicitly says clinicians may prescribe FDA-approved hormone therapy, including estrogen or progesterone, as well as nonhormonal treatments according to history, symptoms and preferences. This confirms an actual prescribing service rather than a website containing only menopause articles. It does not establish that every visitor will receive hormones.
The reviewed pages do not provide a complete US estrogen product list with manufacturer and pharmacy prices. Ask which exact preparation is being proposed and its intended purpose. Local versus systemic estrogen helps separate treatment goals that a broad symptom list can blur. Stella’s page says testosterone was not yet offered when checked; future availability should not be converted into a current service promise.
The average copay is not a personal price
The US FAQ reports an average visit copay of $45 but immediately qualifies coverage by the insurance plan. It describes an account-based benefits estimate and in-network participation. An average from the provider does not identify a particular patient’s deductible, coinsurance or final claim responsibility.
For self-pay, the same source lists an initial visit at $200 and follow-up visits at $90 each. These are visit prices, not a combined hormone-and-care subscription. A superbill may support a request for out-of-network reimbursement, but reimbursement is not guaranteed. Confirm the current payment option and any appointment terms before booking, especially if comparing these figures with a medicine subscription rather than another consultation service.
The prescription leaves a separate pharmacy record
Stella says it sends prescriptions to the patient’s preferred pharmacy after the visit, with medication costs dependent on the insurance plan and pharmacy. That preserves choice, but it also means the appointment price does not include a verified final drug charge. A transmission is not evidence of stock or completed authorization.
Before treating a quoted visit as the total budget, identify the proposed medicine, supply quantity and expected pharmacy payment. The patch-versus-pill guide develops route questions without assigning a preferred method. Ask how the clinician handles a formulary restriction or unavailable product. MyMenopauseRx’s review shows why a preferred-pharmacy workflow needs a clear process when the destination changes after prescribing.
Clinical screening and reassuring stories have limits
The US homepage describes an online health questionnaire, clinical review and monitoring of symptoms and side effects. It also displays patient stories and care examples. We did not evaluate the people, selection process or outcomes behind those stories, and their listed treatments are not recommendations for a reader with similar symptoms.
Stella says laboratory work is not usually needed to begin its care pathway, while leaving the clinician to recommend testing when indicated. That does not mean every complaint can be diagnosed without investigation. FDA’s menopause information describes both potential benefits and risks and advises reporting bleeding after menopause. No screening questionnaire or favorable testimonial should be interpreted as a personal safety determination.
Make the handoff between visits explicit
The strongest practical question for Stella is how its parts connect: the visit, app coach, prescription, pharmacy and any local clinician. A written plan should identify which contact handles a new symptom, how follow-up is arranged and when in-person assessment is needed. App availability alone cannot answer those questions.
Use questions before starting estrogen to organize that conversation and estrogen and progesterone when a uterine-lining protection plan needs explanation. Stella’s US pages document a real menopause care option with clear self-pay visit figures. They leave individual eligibility, the exact medication, final coverage and the effectiveness of care unverified by this publication. Those are the boundaries of a public-record review, even when the service presentation feels comprehensive.
Sources & reading
Source check dates appear with each record below. Provider pages describe their own services; they do not establish clinical superiority.
- Stella US: virtual menopause clinic ↗US provider service page only; no UK prices or delivery terms transferred · Checked 2026-09-28
- Stella US: visits, prescriptions and insurance FAQ ↗US provider FAQ; average copay and self-pay visit charges distinct from pharmacy costs · Checked 2026-09-28
- FDA: Menopause ↗Current federal patient guidance; individualized benefits/risks and prevention limits, no class-wide labeling-change inference · Checked 2026-09-28